Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Stock Report

Market Cap: US$6.8b

Jazz Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 1/6

Jazz Pharmaceuticals has a total shareholder equity of $3.8B and total debt of $5.7B, which brings its debt-to-equity ratio to 151.7%. Its total assets and total liabilities are $11.4B and $7.6B respectively. Jazz Pharmaceuticals's EBIT is $775.6M making its interest coverage ratio 2.9. It has cash and short-term investments of $2.0B.

Key information

151.7%

Debt to equity ratio

US$5.71b

Debt

Interest coverage ratio2.9x
CashUS$1.98b
EquityUS$3.76b
Total liabilitiesUS$7.60b
Total assetsUS$11.36b

Recent financial health updates

Recent updates

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market

Aug 24

Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy

Aug 18

Financial Position Analysis

Short Term Liabilities: JAZZ's short term assets ($3.7B) exceed its short term liabilities ($1.6B).

Long Term Liabilities: JAZZ's short term assets ($3.7B) do not cover its long term liabilities ($6.0B).


Debt to Equity History and Analysis

Debt Level: JAZZ's net debt to equity ratio (99%) is considered high.

Reducing Debt: JAZZ's debt to equity ratio has increased from 53.7% to 151.7% over the past 5 years.

Debt Coverage: JAZZ's debt is not well covered by operating cash flow (18.8%).

Interest Coverage: JAZZ's interest payments on its debt are not well covered by EBIT (2.9x coverage).


Balance Sheet


Discover healthy companies